Ovid Therapeutics Inc. Common StockOVID
Scheduled
Ovid Therapeutics Inc. Common Stock H.C. Wainwright 28th Annual Global Investment Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- Ovid Therapeutics is a clinical-stage company focused on developing novel neurology medicines targeting neural hyperexcitability in the brain.
- The company has two unique clinical-stage programs: OV329 for intractable epilepsies including focal onset seizures and severe pediatric epilepsies, and an oral KCC2 direct activator for multiple CNS conditions including schizophrenia.
- OV329 inhibits the enzyme that catabolizes GABA, increasing inhibitory neurotransmission to reduce seizures, designed to avoid the retinal toxicity seen in the first-generation drug Sabrol.
- Phase 1 studies of OV329 showed increased brain inhibition exceeding the first-generation drug with a clean safety and ophthalmic profile, making it potentially the safest and best-tolerated seizure medicine in development.
- Ovid is currently running a phase 2 study and a photosensitivity study of OV329, with photosensitivity results expected in the next few months and phase 2 results around this time next year.
- OV329 represents a commercial opportunity exceeding $1 billion in focal onset seizures and over $700 million in pediatric epilepsies, with potential expansion into other pediatric indications.
- The KCC2 program involves the first oral direct activator of potassium chloride cotransporter 2, a neuron-specific target implicated in neural hyperexcitability and multiple CNS disorders.
- Ovid’s KCC2 activator, OVI4071, is in phase 1 trials and shows potent activity in psychosis models, with a planned initial indication of acute schizophrenia.
- Preclinical data show that KCC2 activation improves positive, negative, and cognitive symptoms of schizophrenia, restores social behavior, and has rapid and durable effects without sedation.
- Comparative studies indicate Ovid’s KCC2 activators outperform best-in-class antipsychotic drugs in genetic and stimulant-induced schizophrenia models.
- Ovid has established translational biomarkers and is conducting a ketamine challenge study to demonstrate on-mechanism neuroactivity of the KCC2 activator in humans.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring